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Abstract
Objective—To define glomerular filtration rate (GFR) decline, hypertension (HTN) and
proteinuria in subjects with autosomal recessive polycystic kidney disease (ARPKD) and compare
with two congenital kidney disease control groups in the Chronic Kidney Disease in Children
(CKiD) cohort.
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Study design—GFR decline (iohexol clearance), rates of HTN (ambulatory/casual blood
pressures (BPs)), antihypertensive medication usage, left ventricular hypertrophy (LVH) and
proteinuria were analyzed in subjects with ARPKD (n=22) and two control groups: aplastic/
hypoplastic/dysplastic (n=44) and obstructive uropathies (n=44). Differences between study
groups were examined by Wilcoxon rank sum test.
Results—Annualized GFR change in subjects with ARPKD was −1.4 ml/min/1.73m2 (−6%),
with higher decline in subjects age >10 years (−11.5%). However, overall rates of GFR decline did
not differ significantly in subjects with ARPKD vs. controls. There were no significant differences
in HTN or LVH rates, but subjects with ARPKD had a higher percent on ≥3 BP medications (32%
vs.0%, p<0.0001), more ACE inhibitor use (82% vs. 27% vs. 36%, p<0.0005), and less proteinuria
(urine protein: creatinine=0.1 vs.0.6, p<0.005).
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Conclusions—This study reports rates of GFR decline, HTN and proteinuria in a small but wellphenotyped ARPKD cohort. The relatively slow rate of GFR decline in subjects with ARPKD and
absence of significant proteinuria suggest that these standard clinical measures may have limited
utility in assessing therapeutic interventions and highlight the need for other ARPKD kidney
disease progression biomarkers.
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Autosomal recessive polycystic kidney disease (ARPKD) affects approximately 1 in 20,000
children and is genetically and clinically distinct from the more common autosomal
dominant form (ADPKD).1 ARPKD was previously considered a uniformly fatal disease in
affected newborns, but with modern neonatal care, overall mortality has improved
significantly More than 70% survive beyond the newborn period and >80% of those survive
beyond ten years of age.2 ARPKD still carries significant morbidity, with over 40% of
patients progressing to end-stage renal disease (ESRD) by age 15 years.2 The phenotype of
ARPKD, however, is quite variable: some patients progress to ESRD in infancy, whereas
others may not require renal replacement therapy until later childhood and adolescence.3 A
smaller subset present primarily with liver manifestations, typically in adolescence and
young adulthood.4
Despite the significant mortality and morbidity in this population, prospectively collected
data on ARPKD progression are very limited. Most studies have relied on retrospective
analyses and/or registries, which have inherent limitations.3-5 One prospective study
reported measured glomerular filtration rates (GFRs) obtained by 24-hour creatinine
clearance measurements, but did not report rates of GFR decline over time.6 Factors that
may contribute to kidney disease progression, specifically hypertension and proteinuria,
have also not been well characterized.
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The need for these progression data is highlighted by the emergence of novel therapies that
may slow disease progression. Although there are currently no disease-specific therapies that
have been applied in patients with ARPKD, a number of therapies have shown promise in
ARPKD animal models.7,8 Unfortunately, development of treatment trials in patients with
ARPKD is hampered by the paucity of prospective data on GFR decline. In addition,
surrogate markers for kidney disease progression, especially magnetic resonance imaging
(MRI) measurements of kidney volume used to quantitate kidney disease progression in
ADPKD,9 are not valid in ARPKD, as kidney size does not increase with progressive
disease.10
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The objective of this study was to describe the rates of GFR decline, hypertension and
proteinuria in subjects with ARPKD currently enrolled in the prospective Chronic Kidney
Disease in Children (CKiD) study. We also compared findings in the subjects with ARPKD
with those of two control groups with other congenital renal diseases also enrolled in CKiD
in order to better identify ARPKD-specific kidney disease progression features that might
differ from those of other congenital renal diseases.

METHODS
Subjects with ARPKD and controls were selected from among those enrolled in CKiD, a
longitudinal, prospective study of children with mild-moderate chronic kidney disease
(CKD). Over 50 pediatric nephrology sites in the United States and Canada have

J Pediatr. Author manuscript; available in PMC 2017 April 01.

Dell et al.

Page 3

Author Manuscript

participated and/or continue to participate in the study. The inclusion and exclusion criteria
for participation in the study have been reported in detail elsewhere11 (ClinicalTrials.gov:
NCT00327860). Specific entry criteria relevant to this study include age 1-16 years,
estimated GFR of 30-90 ml/min/1.73m2, absence of prior solid organ or hematopoietic stem
cell transplant and absence of severe syndromic disease. Subjects enrolled in CKiD undergo
baseline evaluations, then yearly follow-up visits. The current study included all subjects
with ARPKD currently enrolled in CKiD. Matched controls were obtained from two
diagnostic groups with other congenital renal diseases: (1) aplastic/hypoplastic/dysplastic
disorders (A/H/D); and (2) obstructive uropathies (OU). These groups were chosen as they
were likely to have a similar age distribution as the subjects with ARPKD and are also
primarily tubulointerstitial diseases. Matching was performed in order to distinguish
ARPKD-specific clinical features from those related to early onset CKD in general.
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Participants enrolled in CKiD undergo yearly determination of estimated GFR (eGFR) by
the updated biomarker-based Schwartz GFR estimating formula, eGFR (ml/min per 1.73
m2) = 39.8[ht(m)/Scr(mg/dl)]0.456 [1.8/cystatin C (mg/l)]0.418 [30/BUN(mg/dl)]0.079
[1.076male] [ht(m)/1.4]0.179 and every other year measurements of GFR utilizing iohexol
clearance (iGFR).12 This eGFR formula has show strong correlation with corresponding
iGFR measurements (R=0.92).12 An analysis of subjects with ARPKD confirmed a similar
strong correlation between eGFR and iGFR (R = 0.96, data not shown). Only subjects with
at least two GFR measurements, whether iohexol-measured or estimated, were included.
Subjects with ARPKD were matched 1:2 with A/D/H or OU controls for baseline GFR, age
at study entry and at diagnosis. The primary outcome examined in this study was rate of
GFR decline, reported both as percent (%) decline and absolute decline (expressed as GFR
change in ml/min/1.73m2/year). Both iGFR and eGFR were used in progression
calculations, with preference given to iGFR where available.13 Blood pressure control and
rates of LVH and proteinuria were also investigated as secondary outcomes.
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Casual blood pressures were obtained by standardized auscultatory methods at yearly visits.
Ambulatory blood pressure monitoring (ABPM) was performed every two years utilizing the
SpaceLabs 90217 oscillometric device (SpaceLabs Healthcare, Issaquah, WA).
Echocardiography was also performed every two years to assess for the presence of left
ventricular hypertrophy (LVH), defined as LV mass ≥95th percentile (indexed to Ht2.7 for
age and sex). Methods for obtaining casual blood pressures, ABPMs and echocardiograms
have been described elsewhere.14,15 A subject was considered to have casual hypertension
(HTN) if the baseline blood pressure at the first visit was ≥95th percentile for age/sex/height
percentile.16 Ambulatory HTN was defined as mean wake or sleep systolic blood pressure
(SBP) or diastolic blood pressure (DBP) ≥ 95th percentile or wake or sleep SBP or DBP load
≥ 25% according to published data.17 Proteinuria was defined as a urine protein to creatinine
ratio (UP/C) of ≥0.2 mg/mg from first morning specimens obtained at yearly visits.
Statistical analyses
Demographic and clinical characteristics were reported as median [interquartile range] or
number, n (percent, %) for each group and compared descriptively between groups.
Annualized percent and absolute change in GFR were calculated using individual
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regressions (loglinear and linear, respectively) for each subject incorporating all available
follow-up measurements. Differences (ARPKD vs. each control group) were tested by
Wilcoxon rank-sum test or Fisher's exact test. Matched differences were calculated as the
difference between the value of a subject with ARPKD and the average value of the two
matched controls, and these distributions were tested for difference from zero by Wilcoxon
signed rank test. As a subanalysis, we stratified subjects with ARPKD and control groups by
baseline GFR (≥45 and <45 ml/min/1.73m2) or age at study entry (≥10 and <10 years). All
analyses were performed in SAS 9.3 (SAS Institute, Cary, NC).

RESULTS
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The baseline demographic and clinical features of the subjects with ARPKD and two control
groups are shown in Table I. Subjects with ARPKD and controls were successfully matched
on the selected factors; specifically, baseline GFR, age at study entry and age at diagnosis
were not significantly different between the subjects with ARPKD and both control groups.
The vast majority of subjects were diagnosed before one year of age. Notably, there were
more males in the OU group, likely due to the preponderance of subjects with posterior
urethral valves in that subgroup. There were also more African Americans in the OU control
group compared with the ARPKD group, but this difference was not seen in comparisons of
subjects with ARPKD with the A/H/D control group. Similarly, the ARPKD group had more
subjects who were of Hispanic ethnicity compared with the A/H/D group, but this difference
was not seen in comparisons with the OU group. Rates of prematurity (gestational age less
than 36 weeks) or low birth weight (less than 2500 g) were similar in all three groups.
Renal function (GFR) decline

Author Manuscript
Author Manuscript

Baseline GFR and rates of GFR decline, including both annualized absolute and percent
change, for the subjects with ARPKD and two control groups are summarized in Table II.
Subjects with ARPKD showed a median absolute decline in GFR of −1.4 ml/min/1.73m2 per
year and a percent decline of 6% per year. This was not significantly different from that of
the A/H/D group or the OU group. Analysis of the paired differences in percent GFR decline
showed no significant differences between the subjects with ARPKD and either control
group (data not shown). Because baseline GFR and puberty/older age have been associated
with more rapid decline in renal function,18,19 we performed subanalyses to examine the
impact of these two factors on GFR decline. Subjects with ARPKD and control subjects
were stratified into two baseline GFR groups: GFR <45 or ≥45 ml/min/1.73m2 and two age
groups: <10 vs. ≥10 years of age. Results are summarized in Table III. For both ARPKD
and control groups, subjects with baseline GFR<45 ml/min/1.73m2 showed increased rates
of GFR decline compared with those with higher GFRs. In terms of differences related to
age, it was notable that subjects with ARPKD who were ≥10 years of age showed an 11.5%
per year decline in GFR, which was more than double the rate in subjects with ARPKD <10
years of age. The OU group also showed faster GFR decline in older subjects, whereas the
A/H/D group did not. Statistical testing was not performed due to small numbers in some
subgroups.
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Rates of hypertension, LVH, anti-hypertensive medication use, and proteinuria are
summarized in Table IV. Subjects with ARPKD had similar baseline blood pressures when
compared with the A/H/D and OU controls, and there were no significant differences in rates
of casual or ambulatory hypertension between subjects with ARPKD and either control
group. Rates of LVH also did not differ significantly between subject and control groups.
The subjects with ARPKD did, however, have more antihypertensive use, with over 80%
requiring anti-hypertensive medications. Notably, 32% of subjects with ARPKD were on 3
or more anti-hypertensive medications, whereas none of the control subjects required that
number. Subjects with ARPKD also had more angiotensin converting enzyme inhibitor
(ACEI) and angiotensin receptor blocker (ARB) use compared with the controls. In contrast,
the subjects with ARPKD had significantly less proteinuria than either control group.
Median urine UPC in ARPKD was 0.1 vs. 0.6 in both of the control groups (p<0.005). Only
27% of subjects with ARPKD had proteinuria (UPC>0.2 mg/mg) whereas 68% of the
A/H/D control group and 77% of the OU control group had proteinuria (p<0.005 subjects
with ARPKD vs. each control group).

DISCUSSION
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Cystic kidney disease in ARPKD is characterized by normal collecting tubule (CT)
formation followed by development of progressive fusiform dilatation of the CTs.1 The
disorder affects all CTs, with fusiform cysts progressively replacing normal parenchyma
over time. This ongoing active cystogenic process is accompanied by development of
tubulointerstitial fibrosis. This pathophysiology is in contrast to obstructive uropathies and
congenital dysplasias, in which damage or abnormalities occur during tubular development.
Despite these differences in underlying pathogenesis, there were no significant differences in
percent or absolute GFR decline in the subjects with ARPKD compared with the two control
groups. The subjects with ARPKD had a relatively slow median annualized GFR decline
(−1.4 ml/min/1.73m2 or 6% per year) but also showed substantial variability (IQR, 1-10%
decline per year). Overall, the absolute declines in all three groups were relatively slow, with
overall rates of GFR decline less than 3 ml/min/1.73m2/year.

Author Manuscript

Specific risk factors for ARPKD kidney disease progression have not been reported
previously. Older age/puberty and lower baseline GFR, however, were recently shown to
impact pediatric CKD progression.18-20 In subanalyses, we examined rates of GFR decline
in the subjects with ARPKD and two control groups, stratified by subject age or baseline
GFR. subjects with ARPKD with lower baseline GFRs had higher rates of GFR decline than
those with more intact baseline function. Although small numbers precluded statistical
comparisons, both control groups also demonstrated higher rates of GFR decline in subjects
with lower baseline GFRs. Strikingly, we found a strong association between age and GFR
decline in the subjects with ARPKD with those ≥10 years of age having a decline rate of
11.5% per year, over twice that of younger children. The OU control group also showed
higher rates of decline with older age, though not as dramatic, whereas the A/H/D group did
not.
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Hypertension is a well-established risk factor that is known to influence kidney disease
progression in a wide variety of kidney diseases.20 A previous publication that examined
neurocognition in ARPKD reported data on hypertension and blood pressure medication use
in this ARPKD cohort and the A/H/D control group.21 In the current study, we expanded on
those findings by examining the rates of hypertension and antihypertensive medication use
in subjects with ARPKD in comparison with both A/H/D and OU patient groups. We also
examined LVH rates, which had not been previously reported in the ARPKD cohort.
Consistent with the well-known early and severe hypertension that is characteristic of
ARPKD kidney disease, and with the previous published data, the subjects with ARPKD
had significantly greater anti-hypertensive medication use compared with either control
group. In fact, one-third of subjects with ARPKD were taking 3 or more anti-hypertensive
medications, whereas none of the control subjects were. Despite the high anti-hypertensive
requirements in the subjects with ARPKD, the rates of LVH did not differ among the three
groups, suggesting that blood pressure control was similar in the three groups.

Author Manuscript

Proteinuria is also an important risk factor for kidney disease progression and several recent
studies have highlighted its association with progression in both glomerular and nonglomerular disease in pediatric patients.13,20 Although progression rates were similar in the
subjects with ARPKD compared with the two control groups, the subjects with ARPKD had
significantly lower rates of proteinuria compared with either of the control groups. There
were, in fact, no subjects with ARPKD with heavy proteinuria (UPC >2 g/g, data not
shown). Because all three groups encompass subjects with non-glomerular/primary
tubulointerstitial diseases, one might not have expected them to differ with respect to the
degree of proteinuria. The subjects with ARPKD, however, had substantially higher rates of
ACEI use, likely reflecting the prevailing practice of using these agents as first line therapy
for management of hypertension in this disease.22 The decreased proteinuria rates in the
subjects with ARPKD, therefore, may reflect greater ACEI use, although they may also
reflect the underlying tubulointerstitial disease pathogenesis. Regardless of the underlying
cause for the diminished proteinuria, the findings suggest that proteinuria does not predict
progression in subjects with ARPKD.
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This study had several important limitations. Most notably, the number of subjects with
ARPKD was relatively small. Several other studies have included larger numbers of
subjects, but, as noted previously, these were primarily retrospective studies and registry data
that relied on voluntary self-reporting.3,4 The ARPKD natural history study included 73
genetically confirmed adult and pediatric subjects with ARPKD and prospectively collected
data.6 However, although baseline GFR values on those subjects were reported, no data on
serial GFRs or rates of progression were presented. That study also utilized 24-hour urine
creatinine clearances rather than “gold standard” plasma clearance-based GFR
measurements, such as the iohexol clearance methodology utilized in the CKiD study. In
addition, a significant proportion of their population had undergone liver or kidney
transplants at the time of evaluation. Another limitation of our study is the fact that the
diagnosis of ARPKD in the CKiD cohort was made by the treating nephrologist on the basis
of clinical information, genetic testing or both. Thus, we are not able to definitively exclude
disorders that phenocopy ARPKD (eg, isolated cystic dysplasia).23 Finally, the CKiD cohort
includes subjects with ARPKD with mild to moderate renal disease. Those who were most
J Pediatr. Author manuscript; available in PMC 2017 April 01.
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severely affected were typically excluded from entry based on GFR criteria (i.e., eGFR
requirement of >30 ml/min/1.73m2) and/or a history of antecedent solid organ
transplantation (including liver or kidney transplant). Thus, the data presented may not be
generalizable to all patients with ARPKD.
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Whereas this study provides data on rates of GFR decline, it also highlights the ongoing
challenges of quantifying kidney disease progression in these subjects. The subjects with
ARPKD had relatively low rates of GFR decline as well as substantial variability in GFR
decline; their rates of proteinuria were also very low, in part likely the result of ACEI usage
which also had a favorable impact on BP control. These findings suggest that a large number
of patients would need to be studied for a long period of time in order to assess the impact of
a therapeutic intervention using these standard clinical measures of progression. Given the
rare occurrence of this disease, alternative biomarkers for ARPKD kidney disease
progression are urgently needed in order to undertake therapeutic trials in ARPKD.
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b

22 (50%)
10 (23%)
4 (9%)
7 (17%)
15 (36%)

9 (41%)
1 (5%)
8 (36%)
6 (27%)
4 (18%)

b

b

Low birth weight (<2500g)

Premature birth (<36 weeks)

Hispanic ethnicity

African-American

Male sex

Number (percent). Significant p values (p<0.05) are shown in bold.

b

Median [interquartile range]

a

0.0 [0.0,1.1]

0.1 [0.0,0.4]

a

Age (in years) at diagnosis

b

7.4 [6.1,9.6]

7.9 [4.8,10.1]

a

A/H/D Controls (n=44)

ARPKD Subjects (n=22)

Age (in years) at study entry

Characteristic

0.16

0.34

0.02

0.08

0.60

0.51

0.99

p-value

5 (12%)

4 (9%)

7 (16%)

12 (27%)

36 (82%)

0.0 [0.0,0.8]

8.6 [4.9,10.2]

OU Controls (n=44)

0.47

0.08

0.12

0.046

0.002

0.75

0.55

p-value
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GFR annual percent change

a

GFR annual absolute change (ml/min/1.73m2)

Median [interquartile range].

a

a

Baseline GFR (ml/min/1.73m2)
a

A/H/D Controls (n=44)
46 [29,55]
−1.0 [−3.0,0.5]
−2 [−10,1]

43 [30,57]
−1.4 [−3.5,−0.3]
−6 [−10,−1]

Author Manuscript
ARPKD Subjects (n=22)

0.21

0.72

0.77

p-value

−7 [−12,−1]

−2.7 [−4.3,−0.4]

48 [31,56]

OU Controls (n=44)

Author Manuscript

Summary of Renal Disease Progression

0.80

0.55

0.77

p-value

Author Manuscript
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Author Manuscript
−0.71 (n=23)
−2.79 (n=35)
0.65 (n=9)

−4.91 (n=11)
−5.01 (n=16)
−11.5 (n=6)

GFR ≥45

Age <10 years

Age ≥10 years

−4.36 (n=21)

−6.52 (n=11)

ml/min/1.73m2

GFR <45

A/H/D Controls (n=44)

ml/min/1.73m2

ARPKD Subjects (n=22)

−11.20 (n=12)

−4.54 (n=32)

−5.73 (n=24)

−9.17 (n=20)

OU Controls (n=44)

Subanalyses of Annualized Percent GFR Decline Stratified by Baseline GFR or Age at Study Entry.
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9 (20%)
8/22 (36%)
4 (10%)
18 (41%)
16 (36%)
0 (0%)

7 (32%)
6/12 (50%)
4 (20%)
19 (86%)
18 (82%)
2 (9%)

b

b

c

18 (41%)
0 (0%)
0.6 [0.1,1.5]
28 (68%)

12 (55%)
7 (32%)
0.1 [0.1,0.2]
6 (27%)

a

b

1-2

≥3

Urine protein: creatinine > 0.2 (mg/mg)

Urine protein: Creatinine ratio (mg/mg)

26 (59%)

3 (14%)

0

# of Anti-hypertensives

ARBs

ACEIs

0.003

0.003

<0.0001

0.11

0.0004

0.0004

0.42

0.49

0.37

0.31

p-value

33 (77%)

0.6 [0.2,0.9]

0 (0%)

15 (35%)

29 (66%)

2 (5%)

12 (27%)

15 (34%)

2 (6%)

20/28 (71%)

6 (14%)

72 [60,89]

OU Controls (n=44)

0.0002

0.0001

<0.0001

0.60

<0.0001

0.0001

0.19

0.28

0.10

0.56

p-value

Number positive/number studied (percent). Significant p values (p<0.05) are shown in bold ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVH, left ventricular
hypertrophy

c

Number (percent)

b

b

Anti-hypertensive medication use

LVH

b,c

Ambulatory hypertension

b
Casual hypertension ,

Median [interquartile range]

a

68 [31,94]

83 [44,97]

a

Baseline (casual) systolic blood pressure (SBP) percentile

A/H/D Controls (n=44)

ARPKD Subjects (n=22)

Characteristic
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Hypertension and Proteinuria in ARPKD Subjects and Controls

Author Manuscript
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